Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies

[1]  R. Salem,et al.  Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies , 2012, Current Treatment Options in Oncology.

[2]  Michael A. Choti,et al.  Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[3]  M. V. Van Vledder,et al.  Body composition and outcome in patients undergoing resection of colorectal liver metastases , 2012, The British journal of surgery.

[4]  Michael J. Englesbe,et al.  Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma , 2011, Annals of Surgical Oncology.

[5]  A. Benson,et al.  Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. , 2011, Gastroenterology.

[6]  Mark G van Vledder,et al.  Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  G. Cabibbo,et al.  Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation , 2011, Alimentary pharmacology & therapeutics.

[8]  Eleni Liapi,et al.  Transcatheter intraarterial therapies: rationale and overview. , 2011, Radiology.

[9]  Chia-Yang Hsu,et al.  Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  Chia-Yang Hsu,et al.  Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma , 2011, Hepatology international.

[11]  R. Omary,et al.  Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. , 2011, AJR. American journal of roentgenology.

[12]  D. Fraker,et al.  Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol , 2011, Cancer.

[13]  D. Cella,et al.  Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. , 2011, Annual review of medicine.

[14]  K. McMasters,et al.  Imaged Guided Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Hepatic Metastases from Melanoma: Early Outcomes from a Multi-Institutional Registry , 2011, The American surgeon.

[15]  A. Kibel.  Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial , 2010 .

[16]  E. Van Cutsem,et al.  Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Douglas E Schaubel,et al.  Sarcopenia and mortality after liver transplantation. , 2010, Journal of the American College of Surgeons.

[18]  L. Birdsell,et al.  Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Makary,et al.  Frailty as a predictor of surgical outcomes in older patients. , 2010, Journal of the American College of Surgeons.

[20]  R. Dhanasekaran,et al.  Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[21]  L. Birdsell,et al.  Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Qiang Chen,et al.  Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. , 2010, Chinese journal of cancer.

[23]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[24]  P. Cawthon,et al.  Sarcopenia: etiology, clinical consequences, intervention, and assessment , 2009, Osteoporosis International.

[25]  Suzanne Satterfield,et al.  Do Muscle Mass, Muscle Density, Strength, and Physical Function Similarly Influence Risk of Hospitalization in Older Adults? , 2009, Journal of the American Geriatrics Society.

[26]  L. Kuller,et al.  Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes , 2009, Diabetes Care.

[27]  L. Mccargar,et al.  Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment , 2009, Clinical Cancer Research.

[28]  J. Sloan,et al.  Patient‐physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer , 2008, Cancer.

[29]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[30]  A. Benson,et al.  Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. , 2008, Radiology.

[31]  J. Souquet,et al.  Chimio-embolisation des carcinomes hépatocellulaires : analyse multivariée des facteurs pronostiques de survie après la première séance , 2008 .

[32]  W. Helton,et al.  A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. , 2007, American journal of surgery.

[33]  L. Kuller,et al.  Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes , 2007, Diabetes Care.

[34]  S. Kritchevsky,et al.  The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  K. Fearon,et al.  Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.

[36]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[37]  J. Dancey,et al.  Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. , 2005, Journal of vascular and interventional radiology : JVIR.

[38]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[39]  M. Soulen,et al.  Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. , 2004, Gastroenterology.

[40]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[41]  R. Sanford,et al.  Morbidity of Second-Look Surgery in Pediatric Central Nervous System Tumors , 2001, Pediatric Neurosurgery.

[42]  J. Sloan,et al.  A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Olschewski,et al.  Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single‐center analysis including 132 patients , 1998, International journal of cancer.

[44]  Ding‐Shinn Chen,et al.  Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. , 1998, Hepato-gastroenterology.

[45]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[46]  D. Kerr,et al.  Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? , 1996, European journal of cancer.

[47]  P. Rudolph,et al.  Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. , 1996, Urology.

[48]  M. Tamburini,et al.  Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. , 1996, European journal of cancer.

[49]  G. Idéo,et al.  Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors , 1994, Hepatology.

[50]  D. Kerr,et al.  A comparison of regional and systemic chemotherapy for hepatic metastases. , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  V. Mor,et al.  Clinical symptoms and length of survival in patients with terminal cancer. , 1988, Archives of internal medicine.

[52]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.

[53]  K. Eichler,et al.  Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. , 2009, Radiology.

[54]  A. Rode,et al.  [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session]. , 2002, Gastroenterologie clinique et biologique.

[55]  J. Figueras,et al.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization , 2000, Cancer.

[56]  M. Maltoni,et al.  Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. , 1994, European journal of cancer.

[57]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .